INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences Holdings Corporation is a global medical technology company that manufactures and sells medical technologies and products. The company operates in two reportable business segments: Codman Specialty Surgical ("CSS") and Tissue Technologies ("TT"). The CSS segment accounts for approximately 70% of total revenue and includes market-leading technologies and instruments used in specialties such as neurosurgery, neurocritical care, and otolaryngology (ear, nose, and throat or "ENT"). Integra LifeSciences is a world leader in neurosurgery and one of the top three providers in the U.S. for instruments used in precision, specialty, and general surgical procedures. The TT segment generates about 30% of overall revenue and focuses on wound reconstruction and care, as well as private label products. The company was the first to receive an FDA claim for regeneration of dermal tissue and is a world leader in regenerative technology. They have developed numerous product lines from this technology for applications including burn and deep tissue wounds, repair of dura mater in the brain, and repair of nerves and tendons. Integra LifeSciences has expanded its regenerative technology business to include neurosurgical products, ENT, surgical instruments, and advanced wound care through global acquisitions and product development. Within neurosurgery, the company is a global leader in neuro-access, neuro-surgical, and neuro-monitoring technologies.